Use Cases

Microdosing and Sleep: What the Research Actually Suggests

Microdosing may affect sleep indirectly through anxiety and stress, but there is no direct controlled evidence for a sleep-specific benefit. Timing matters because late doses may disrupt sleep.

Updated May 25, 2026

Microdosing for Addiction: The Full-Dose Signal and the Microdose Gap

Psilocybin shows notable full-dose trial results for alcohol and smoking cessation, while microdosing evidence remains observational and early-stage. A neutral explanation of where the stronger evidence actually sits.

Updated May 25, 2026

Microdosing for ADHD and Focus: What Research Actually Shows

Microdosing for ADHD and focus is widely reported but variable — some improve, some worsen. A neutral account of why individual response differs more here than for any other use case, and why careful self-observation matters.

Updated May 25, 2026

Microdosing for Anxiety: What the Evidence Actually Supports

Anxiety is the most consistently reported microdosing use case. A neutral review of what observational studies, biological mechanisms, and full-dose trials do and do not establish about sub-perceptual dosing.

Updated May 25, 2026

Microdosing for Chronic Pain: What the Research Actually Suggests

Microdosing for chronic pain remains an early-stage research area. Interest centers on fibromyalgia and central sensitisation through possible 5-HT2A mechanisms, but evidence remains preliminary and indirect.

Updated May 25, 2026

Microdosing for Creativity: What Studies Actually Show

Creativity is the most widely reported microdosing benefit, but controlled evidence remains weak. Some studies suggest changes in cognitive flexibility, while broader creativity claims remain largely anecdotal.

Updated May 25, 2026

Microdosing for Depression: What the Evidence Supports, and What It Doesn't

Depression is one of the most reported microdosing use cases and also the area with the strongest full-dose psilocybin trials. A neutral explanation of what transfers to microdosing, what does not, and why SSRIs complicate the picture.

Updated May 25, 2026

Microdosing for OCD: What Research Actually Suggests

OCD has one of the strongest serotonergic rationales among psychedelic use cases and an early psilocybin study showing symptom reductions. However, microdosing-specific evidence remains minimal and preliminary.

Updated May 25, 2026

Microdosing for PTSD: What Research Actually Suggests

PTSD microdosing remains early-stage. Fear-extinction pathways provide a plausible rationale, but evidence is observational and trauma resurfacing presents real risks requiring caution.

Updated May 25, 2026

Microdosing for Stress and Burnout: What Research Actually Suggests

Stress and burnout reports largely mirror the anxiety findings around reduced reactivity and perspective shifts. Evidence remains observational, placebo-sensitive, and limited by burnout's structural causes.

Updated May 25, 2026

Psilocybin for Cluster Headaches: Real Evidence, but Not Microdosing

Cluster-headache and migraine research involves periodic perceptible doses rather than daily sub-perceptual microdosing. A neutral explanation of where the real evidence sits and why the protocols differ.

Updated May 25, 2026

Psilocybin for End-of-Life Distress: Strong Evidence, but Full-Dose

Landmark Johns Hopkins and NYU trials found large, durable reductions in existential distress after single supervised full doses of psilocybin — evidence for a different intervention than microdosing.

Updated May 25, 2026